Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

NCT07106723 | Recruiting Phase 2

• 1 other identifier: IIT2025051
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL

Conditions

CD7 Positive; T - Cell Lymphoma

Outcome Measures

Primary Outcomes (2)

• PFS rate at 1 year after ASCT conbined with CD7-CART

  at 1 year after ASCT conbined with CD7-CART

• Incidence and Severity of Adverse Events after ASCT conbined with CD7-CART

  Refer to irAE grading standard

  during 2 years after ASCT conbined with CD7-CART

Secondary Outcomes (9)

• Duration of Response (DOR)

  during 2 years after ASCT conbined with CD7-CART

• Progression-free Survival (PFS)

  during 2 years after ASCT conbined with CD7-CART

• MRD negetive rate

  at 3 or 6 month after ASCT conbined with CD7-CART

• Time to Response (TTR)

  during 2 years after ASCT conbined with CD7-CART

• Overall Survival (OS)

  during 2 years after ASCT conbined with CD7-CART

Study Arms (1)

ASCT conbined with CD7-CART.

EXPERIMENTAL

Drug: ASCT+CD7-CART

Interventions

ASCT+CD7-CART DRUG

Intravenous infusion of CD7-CART 3 days after ASCT

ASCT conbined with CD7-CART.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• With the subject's consent and having signed the informed consent form, willing and capable of adhering to the planned visits, study treatment, laboratory tests and other trial procedures;
• Age 18 to 65 years old, both male and female;
• Confirmed as T-cell non-Hodgkin's lymphoma type (including T-lymphoblastic lymphoma/leukemia) according to the World Health Organization's classification of hematopoietic and lymphoid tissue tumors (2022), and meeting one of the following three conditions: 1) Newly diagnosed with high-risk factors, such as Ann Arbor stage III/IV, large mass, bone marrow invasion, central nervous system (CNS) invasion, ETP phenotype, RAS activating mutation, TP53 deletion/mutation, etc., as assessed by the investigator; 2) Not achieving PR or better response after induction and consolidation therapy; 3) Patients not considered for allogeneic hematopoietic stem cell transplantation;
• Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening;
• With appropriate organ function: 1) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN), if the investigator determines that the abnormal ALT and AST are due to the disease (such as liver infiltration or bile duct obstruction), the indicators can be relaxed to ≤ 5 times ULN; 2) Total serum bilirubin ≤ 2 times ULN, except for patients with Gilbert's syndrome; patients with Gilbert's syndrome and total bilirubin ≤ 3 times ULN and direct bilirubin ≤ 1.5 times ULN can be included; 3) Serum creatinine clearance rate ≥ 30 mL/min; 4) International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN; 5) Possessing the minimum level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and non-oxygen-dependent blood oxygen saturation ≥ 92%; 6) Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion and pleural effusion.
• Women of childbearing age have a negative blood/urine pregnancy test within 7 days before infusion. Any male and female patients with fertility must agree to use effective contraceptive methods throughout the study and for at least 2 years after the administration of study treatment.

You may not qualify if:

• Subjects with one or more of the following are not eligible for this study:
• History of allergy to any of the components in the cell product;
• Severe cardiac disease, including but not limited to: Myocardial infarction, cardiac angioplasty, or stenting within 6 months prior to signing the ICF; unstable angina; severe cardiac arrhythmias; History of severe non-ischemic cardiomyopathy; Congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), NYHA score listed in Appendix II
• Have a history of autologous/allogeneic hematopoietic stem cell transplantation;
• stroke or seizure within 6 months prior to signing the ICF;
• Have autoimmune diseases, immunodeficiencies or other diseases that require immunosuppressant treatment;
• Within 3 years prior to signing the ICF, have malignancies other than T-cell hematologic tumors, except for adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer after radical resection, carcinoma in situ of the duct in situ after radical resection, carcinoma in situ of other sites one year after radical resection, and there has been no treatment during the screening period and there is no sign of recurrence;
• presence of uncontrolled active infection;
• Unstable systemic diseases judged by the investigator: including but not limited to severe hepatic, renal or metabolic diseases requiring drug treatment;
• Any of the following within 4 weeks prior to lymphocyte collection:
• The DNA detection value of hepatitis B virus (HBV) in peripheral blood was higher than the lower limit of detection; Positive for hepatitis C virus (HCV) antibody and positive for peripheral HCV-RNA; positive for human immunodeficiency virus (HIV) antibodies; positive for syphilis antigen or antibody; Positive for CMV-DNA (10) application of prednisone (or equivalent amounts of other corticosteroids) in excess of 5mg/day within 1 week prior to lymphocyte collection; (11) Have used any CAR-T cell products or other genetically modified T-cell therapies; (12) Received CD7-targeted therapy; (13) History of live vaccination within 4 weeks prior to signing the ICF; (14) Have a history of alcoholism, drug abuse, or mental illness; (15) Other situations that the investigator considers unsuitable to participate in this study.

Sponsors & Collaborators

• Institute of Hematology & Blood Diseases Hospital, China: lead
• Hebei Taihe Chunyu Biotechnology Co., Ltd: collaborator

Study Sites (1)

Blood Disease Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China

RECRUITING

MeSH Terms

Conditions

Lymphoma, T-Cell

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Liang Huang, Dr

CONTACT

022-23608359; huangliang@ihcams.ac.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: ASCT conbined with CD7-CART

Study Record Dates

• First Submitted: July 30, 2025
• First Posted: August 6, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): January 7, 2029
• Study Completion (Estimated): January 7, 2030
• Last Updated: August 6, 2025

Record last verified: 2025-07

Locations

CN (1)